Novel anti-arrhythmic agents for the treatment of atrial fibrillation

Current Opinion in Pharmacology

Volumn 7, Issue 2, 2007, Pages 214-218

  Wettwer, Erich ^a   Christ, Torsten ^a   Dobrev, Dobromir ^a   Ravens, Ursula ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZD 7009; AZIMILIDE; CLAMIKALANT; DOFETILIDE; FLECAINIDE; IBUTILIDE; LIDOCAINE; NIP 142; PILSICAINIDE; POTASSIUM CHANNEL BLOCKING AGENT; PROPAFENONE; QUINIDINE; ROTIGAPTIDE; RSD 1235; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TEDISAMIL; TERIKALANT; TERTIAPIN; UNCLASSIFIED DRUG; VERAPAMIL;

CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; COMORBIDITY; DEFIBRILLATION; DOG; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SPECIFICITY; DRUG USE; EXPERIMENTAL MODEL; GOAT; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART SURGERY; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SELF MEDICATION; SIDE EFFECT; SINUS RHYTHM; SUDDEN DEATH; TORSADE DES POINTES;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ELECTROPHYSIOLOGY; HEART ATRIA; HUMANS; VENTRICULAR REMODELING;

EID: 33947249209     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.10.007     Document Type: Review

References (46)

1. Humphries K.H., Kerr C.R., Steinbuch M., Dorian P., and and for the Canadian Registry of Atrial Fibrillation (CARAF) Investigators. Limitations to antiarrhythmic drug use in patients with atrial fibrillation. CMAJ 171 (2004) 741-745
2. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415 (2002) 219-226
3. Dobrev D. Electrical remodeling in atrial fibrillation. Herz 31 (2006) 108-112
4. Pacifico A., and Henry P.D. Class I or class III agents for atrial fibrillation: are we asking the right question?. Pacing Clin Electrophysiol 26 (2003) 1613-1619
5. 2+-handling in human chronic atrial fibrillation. Circulation 114 (2006) 670-680
6. Zipes D.P., Camm A.J., Borggrefe M., Buxton A.E., Chaitman B., Fromer M., Gregoratos G., Klein G., Moss A.J., Myerburg R.J., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the european heart rhythm association and the heart rhythm society. Circulation 114 (2006) e385-e484
7. Nattel S., Kneller J., Zou R., and Leon L.J. Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies. J Cardiovasc Electrophysiol 14 (2003) S133-S139
8. Kneller J., Kalifa J., Zou R., Zaitsev A.V., Warren M., Berenfeld O., Vigmond E.V., Leon L.J., Nattel S., and Jalife J. Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ Res 96 (2005) e35-e47. This work proved the efficacy of the selective sodium channel blocker tetrodotoxin to terminate atrial fibrillation in the sheep heart. Tetrodotoxin dose-dependently increased the size of the primary re-entry circuits, decreased the generation of secondary wavelets by wavebreak, and terminated atrial fibrillation. These findings clearly show that selective blockade of sodium channels is, in principle, an effective option for termination of AF and emphasizes the necessity to develop selective sodium channels blockers.
9. Marrouche N.F., Reddy R.K., Wittkowsky A.K., and Bardy G.H. High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized, double-blind crossover trial. Am Heart J 139 (2000) e8-e11
10. Alboni P., Botto G.L., Baldi N., Luzi M., Russo V., Gianfranchi L., Marchi P., Calzolai M., Solano A., Baroffio R., and Gaggioli G. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 351 (2004) 2384-2391
11. Eijsbouts S., Ausma J., Blaauw Y., Schotten U., Duyitschaefer M., and Allessie M.A. Serial cardioversion by class IC drugs during 4 months of persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol 17 (2006) 648-654. Persistent AF in the goat affects the efficacy of anti-arrhythmic drugs. The authors clearly show that progressive atrial remodelling increases the size of the cycle length needed to terminate AF, thereby reducing the efficacy of class IC drugs to cardiovert the arrhythmia.
12. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
13. Plewan A., Lehmann G., Ndrepepa G., Schreieck J., Alt E.U., Schomig A., and Schmitt C. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 16 (2001) 1504-1510
14. Kuhlkamp V., Schirdewan A., Stangl K., Homberg M., Ploch M., and Beck O.A. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 36 (2000) 139-146
15. Pratt C.M., Singh S.N., Al-Khaladi H.R., Brum J.M., Holroyde M.J., Warcello S.R., Schwartz P.J., Camm A.J., and Investigators ALIVE. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 43 (2004) 1211-1216
16. Kerr C.R., Conolly S.J., Kowey P., Page R.L., Prittchet E.L., Ruday M.Y., Ruzyllo W., Wilkinson W.E., and Investiagtors A-STAR. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol 98 (2006) 215-218
17. Lombardi F., Borggrefe M., Ruzyllo W., and Lüderitz B. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Eur Heart J 18 (2006) 2224-2231
18. Clements-Jewery H., Kanaganayagam G.S., Kabra R., and Curtis M.J. Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts. Br J Pharmacol 147 (2006) 468-475
19. Paul A.A., Witchel H.J., and Hancox J.C. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 136 (2002) 717-729
20. + channel blocker, pilsicainide, on HERG current expressed in HEK-293 cells. J Cardiovasc Pharmacol 42 (2003) 410-418
21. Goldstein R.N., and Stambler B.S. New antiarrhythmic drugs for prevention of atrial fibrillation. Prog Cardiovasc Dis 48 (2005) 193-208
22. Page R.L., and Roden D.M. Drug therapy for atrial fibrillation: Where do we go from here?. Nat Rev Drug Discov 4 (2005) 899-910
23. K,ACh channels in the absence of acetylcholine are expected to contribute to the induction and perpetuation of AF even in the absence of abnormal vagal nerve activation, and could represent a novel therapeutic target for treatment of this arrhythmia.
24. Gögelein H., Brendel J., Steinmeyer K., Strubing C., Picard N., Rampe D., Kopp K., Busch A.E., and Bleich M. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 183-192
25. Blaauw Y., Gögelein H., Tieleman R.G., van Hunnik A., Schotten U., and Allessie M.A. Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 110 (2004) 1717-1724
26. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110 (2004) 2299-2306
27. Fedida D., Orth P.M., Chen J.Y., Lin S., Plouvier B., Jung G., Ezrin A.M., and Beatch G.N. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 16 (2005) 1-12
28. Na and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 70 (2006) 486-496
29. + current in rat ventricular myocytes. Am J Physiol 257 (1989) H1746-H1749
30. + currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther 254 (1990) 560-569
31. Wettwer E., Himmel H.M., Amos G.J., Li Q., Metzger F., and Ravens U. Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br J Pharmacol 125 (1998) 659-666
32. Hohnloser S.H., Dorian P., Straub M., Beckmann K., and Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent onset atrial fibrillation or atrial flutter. J Am Coll Cardiol 44 (2004) 99-104
33. Goldstein R.N., Khrestian C., Carlsson L., and Waldo A.L. AZ7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 15 (2004) 1444-1450
34. Persson F., Carlsson L., Duker G., and Jacobson I. Blocking characteristics of hERG, hNav1.5 and hKvLQT1/hminK after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Electrophysiol 16 (2005) 329-341
35. Persson F., Carlsson L., Duker G., and Jacobson I. Blocking characteristics of hKv1.5 and hKv4. 3/hKChIP2. 2 after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Pharmacol 46 (2005) 7-17
36. Carlsson L., Chartier D., and Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol 47 (2006) 123-132
37. Mori K., Hara Y., Saito T., Masuda Y., and Nakaya H. Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms. Circulation 91 (1995) 2834-2843
38. Brandts B., Van Bracht M., Dirkmann D., Borchard R., Wickenbrock I., Prull M.W., Meine M., and Trappe H.J. Perspectives and limitations in the treatment of vagus-induced atrial fibrillation. Insights from cellular pharmacology. Med Klin 99 (2004) 341-346
39. K,ACh channels could be a novel therapeutic option for AF.
40. Matsuda T., Ito M., Ishimaru S., Tsuruoka N., Saito T., Iida-Tanaka N., Hashimoto N., Yamashita T., Tsuruzoe N., Tanaka H., and Shigenobu K. Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1/4 channel. J Pharmacol Sci 101 (2006) 303-310
41. Guerra J.M., Everett IV T.H., Lee K.W., Wilson E., and Olgin J.E. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 114 (2006) 110-118
42. Kur, fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation 114 (2006) 1234-1242. An elegant demonstration that blockade of potassium channels might be a novel therapeutic approach for prevention of atrial contractile dysfunction in the post-cardioversion period.
43. Cammilli L., Mugelli A., Grassi G., Alcidi L., Melissano G., Menegazzo G., and Silvestri V. Implantable pharmacological defibrillator (AIPhD): preliminary investigations in animals. Pacing Clin Electrophysiol 14 (1991) 381-386
44. Hoffmann E., Sulke N., Edvardsson N., Ruiter J., Lewalter T., Capucci A., Schuchert A., Janko S., and Camm J. Atrial fibrillation therapy trial investigators: new insights into the initiation of atrial fibrillation: a detailed intraindividual and interindividual analysis of the spontaneous onset of atrial fibrillation using new diagnostic pacemaker features. Circulation 113 (2006) 1933-1941
45. Schwartzman D., Harvey M.N., Hoyt R.H., Koehler J.L., Ujhelyi M.R., and Euler D.E. Utility of adjunctive single oral bolus propafenone therapy in patients with atrial defibrillators. Europace 8 (2006) 211-215
46. Rho R.W., and Page R.L. Asymptomatic atrial fibrillation. Prog Cardiovasc Dis 48 (2005) 79-87